GlassScriptPhysician profile
Raluca Szentes
NPI 1215719026
$2,196.28
in general payments reported to CMS, 2019-2025
16 companies · $841 in 2025
The $841 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,355 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,145 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.33 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.11 | 2024-2025 | |
| Janssen Biotech, INC. | $396.95 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $251.22 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.36 | 2024-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $229.74 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.26 | 2024 | Xifaxan, Plenvu |
| Lilly USA, LLC | $130.00 | 2024-2025 | Omvoh, Zepbound |
| Qol Medical, LLC | $122.19 | 2025 | Sucraid |
| Pfizer INC. | $46.87 | 2024 | |
| Celltrion USA INC. | $37.09 | 2024-2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $30.24 | 2024 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $24.00 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $22.78 | 2024 | |
| Intercept Pharmaceuticals, INC. | $20.56 | 2024 | |
| Merck Sharp & Dohme LLC | $16.17 | 2024 | Dificid |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $10.74 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raluca Szentes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.